Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Here’s why the AVITA (ASX:AVH) share price is going bananas

The AVITA Medical Inc (ASX:AVH) share price is up more than 15% after giving a FY20 second quarter update. 

The AVITA Medical Inc (ASX: AVH) share price is up more than 15% after giving a FY20 second quarter update.

Avita is a regenerative medicine company that is developing and commercialising a technology platform that enables point of care autologous skin restoration.

AVITA Q2 update

Avita said that in the second quarter ending 31 December 2020, its US based RECELL revenue is expected to be $5 million, compared to $5 million in the previous quarter. This was an increase of 62%, or $1.9 million, compared to the December quarter in 2019.

Total global revenue is expected to be $5.1 million in the second quarter, compared to $5.1 million in the previous quarter. Total global revenue increased by 57% over the same quarter in the prior year, this was an increase of $1.8 million in dollar terms.

Avita said that it enrolled nine additional patients into its study assessing the use of the RECELL system to treat stable vitiligo. The company added seven new accounts during this second quarter, bringing the overall total to 93 accounts. The estimated procedural volumes were 485 in the second quarter of 2021, compared to 496 in the previous quarter.

The company’s balance sheet finished the quarter with $59.8 million of cash, a decrease of $6 million from the end of the September 2020 quarter.

Management comments

Avita Medical Chief Executive Officer Dr Mike Perry said: “I’m pleased with our team’s commercial execution during these challenging times. We continue to make solid progress in our pipeline initiatives, and I look forward to updating you further during our quarterly earnings call.”

Time to buy Avita shares?

Avita does seem to have an impressive product which delivers good results. It also boasts of a total addressable market worth billions that it could tap into. I’m not a medical expert at all, so I’m not sure how successful Avita can be over the long term. For the patients’ sake, I hope Avita is able to help as many people as possible.

This ASX share could be an opportunity, considering how much it has fallen since early 2020, but I prefer to stick with investments I have a better understanding of. That’s one of the main reasons why I like Pushpay Holdings Ltd (ASX: PPH) shares, it also has big goals like Avita – but it’s demonstrating excellent economies of scale right now with its profit growth.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content